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Background and the purpose of the study: Rizatriptan is used effectively for the treatment of migraine
headache. In this study, a simple, rapid and low cost spectrophotometric method based on the ion-pair
complexation is proposed for the determination of rizatriptan in raw material and dosage forms.
Methods: The ion-pair complexation using bromocresol green as reagent was performed in a buffer solution and
the absorbance was measured by a spectrophotometer. The ion-pair formation conditions were optimized and the
accuracy and precision of the method were calculated.
Results and major conclusion: Best results were achieved by using 6 ml of the bromocresol green reagent in the
presence of phosphate buffer (pH 3.0). The stoichiometry of the resulted complex was 1:1. The within-day and
between-day precision values were lower than 2.9 and 1.8 percent for the calibration range of 0.5–50 and
10–100 μg/ml, respectively. The proposed method was successfully used for the determination of rizatriptan in
dosage forms without any interference.
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Rizatriptan benzoate (Figure 1), N, N-dimethyl-5-(1H, 1,
2, 4-triazol-1-ylmethyl)-1H-indole-3-ethanamine benzoate,
binds selectively with high affinity to human 5-
hydroxytryptamine 1B/1D receptor. Clinical trials have
demonstrated the effectiveness of oral rizatriptan for the
treatment of migraine headache [1-3].
Several analytical methods based on liquid chromatog-
raphy/ tandem mass spectrometry [4,5] or high perform-
ance liquid chromatography with fluorescence detection
[6] has been reported for determination of rizatriptan in
biological fluids. HPLC [7-9] and HPTLC [10] methods
have also been used for quantitative determination of
rizatriptan in bulk drug or pharmaceutical dosage forms.
Furtheremore, few spectrophotometric methods were
reported in the literature for the determination of riza-
triptan in dosage forms [11-16]. Some of these methods* Correspondence: souri@sina.tums.ac.ir
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reproduction in any medium, provided the orare based on ion-pair complexation, redox-complexation
reaction in the presence of iron ion and also oxidative
coupling reactions. In most previously reported spectro-
photometric methods a relatively narrow linear range or
high limit of quantification has been obtained.
As rizatriptan is not official in USP or BP, there is still
a demand for new simple, sensitive and rapid methods
in order to determine the drug in pharmaceutical dos-
age forms. The present study deals with the development
and validation of a sensitive extractive spectrophotometric
method using bromocresol green (BCG) as ion-pair com-
plexation reagent. The BCG reagent is relatively cheap and
has been used before in our laboratory for determination
of some other drugs [17-19]. Spectrophotometric methods
are rapid, cost effective, simple and acceptable which use
very routine and available instruments in every quality
control laboratory. The validated method could be suc-
cessfully used for routine quality control analysis with-
out any special sample preparation before determination.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chemical structure of rizatriptan.
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Apparatus
A double beam UV-visible spectrophotometer (UV-160,
Shimadzu, Japan) in the wavelength range of 200–800
was used for spectrophotometric measurements.
A Waters HPLC system consisting of a Model 515
pump, a Model 717 plus Autosampler and a Model 486
UV-visible detector (All from Waters, Milford, USA) were
used. Multi-channel Chrom&Spec software for chroma-
tography (version 1.5×) was used for data processing.
Chemicals
Rizatriptan benzoate (purity 99.8%) was from Merck
(Batch No: 000705126 0048038) and was kindly provided
by Food and Drug Laboratory Research Center, Ministry
of Health, Tehran, Iran. Bromocresol green (BCG) and
the other analytical grade chemicals were purchased
from Merck (Darmstadt, Germany).
Standard solutions
A standard solution of rizatriptan benzoate (5 × 10-4 M)
was prepared by dissolving 13.5 mg of the drug in
100 ml of distilled water.Figure 2 (A) Absorption spectra of rizatriptan, (B) BCG, and (C) the io
(5 × 10-4 M) and 6 ml of BCG (5 × 10-4 M).A 5 × 10-4 M solution of BCG was prepared by dissol-
ving 349 mg of BCG in 1000 ml of distilled water by
adding 2 ml of 0.1 M NaOH for better solubility.
The phosphate buffer (0.1 M) was prepared by dissol-
ving 1.78 g of NaH2PO4 in 1000 ml of distilled water.
The pH value was adjusted to 3.0.
The Britton- Robinson buffers in the pH range of 2–7
were prepared from an equal mixture of 0.1 M acetic
acid, 0.1 M boric acid and 0.1 M phosphoric acid. The
pH value was adjusted using a 1 M NaOH solution.
General procedure for sample preparation
An aliquot of 2 ml of rizatriptan solution (5 × 10-4 M),
1 ml of buffer solution (pH 3), 6 ml of BCG reagent (5 ×
10-4 M), and 1 ml of distilled water were transferred to a
100 ml separating funnel. The mixture was extracted
three times using 5, 3 and 2 ml portions of chloroform.
The separating funnel was vigorously shacked for 30 sec-
onds for extraction. The organic phase was separated
and dehydrated by passing over anhydrous sodium sul-
fate and was transferred to a 10 ml volumetric flask. The
volume was completed with chloroform and the absor-
bance was measured at 416 nm against a reagent blank.
Optimization of the reaction conditions
Selection of the optimum pH
The effect of pH on ion-pair complex formation was stu-
died by using the general procedure and Britton-Robinson
buffers in the range of 2–7. Also, different kinds of buffers
(phthalate, acetate, phosphate) at the same pH value were
studied to find out the effect of buffer type.
Selection of the reagent amount
Using 2 ml of rizatriptan solution (5 × 10-4 M) and 1 ml
of phosphate buffer (pH 3.0), different amounts of BCG


















Figure 3 The effect of pH of the buffer (Britton-Rabinson) on
the ion-pair complex formation using 2 ml of rizatriptan



















Figure 4 The effect of BCG (5 × 10-4 M) amount on the
absorbance of the ion-pair complex at 416 nm using 2 ml of
rizatriptan (5 × 10-4 M).
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416 nm.
Selection of the extracting solvent
To find out the best extracting solvent, chloroform;
dichloromethane; ethyl acetate; and diethyl ether were
used as extracting solvents and the absorbance of the
resulting ion-pair complexes were compared.
The effect of the reaction time
The effect of time on the ion-pair complex formation
was studied at various time intervals in the range of
0–60 min.
Stoichiometric relationship
The Job’s method of continuous variations was applied
to find out the stoichiometric ratio of the ion-pair com-
plexation. Different volumes of rizatriptan and BCG, at
equal molar concentrations (4 × 10-4 M), were mixed
with a fixed total volume and the absorbance of the
resulting ion-pair complex was measured according to
the general procedure. The resulting absorbance was
plotted over the mole ratio of rizatriptan.
Determination of rizatriptan in dosage forms
Twenty Rizatriptan tablets (5 mg) (Farabi Pharmaceutical
Co, Iran) were finely powdered using a mortar and pestle.
Next, an amount of the resulted power equivalent to one
tablet (5 mg of rizatriptan) was accurately weighed and
transferred to a 100 ml volumetric flask and about 70 ml
of distilled water was added. The mixture was sonicated
for 15 min and made up to volume by the same solvent.
After filtration through a 0.45 μm syringe filter, the
concentration of rizatriptan was measured according to
the general procedure. The amount of rizatriptan was cal-
culated by comparing the obtained absorbance with a
standard solution at the same concentration. The same
procedure was also performed for determination of rizatrip-
tan by HPLC using a previously published method [20].Relative recovery
The relative recovery of rizatriptan from dosage form
was evaluated by standard addition method. Rizatriptan
standard solution at concentration level of 40 μg/ml was
added to a solution obtained from tablet powder equal
to one tablet. After ion-pair complexation and according
to the general procedure, the absorbance of this solution
was compared with a standard solution at 40 μg/ml after
subtraction of the absorbance of a tablet powder. The
relative recovery was then calculated.
Linearity
Six series of rizatriptan solutions in the range of
0.5–50 μg/ml and also 10–100 μg/ml were prepared and
the absorbance was measured according to the general
procedure. The calibration curves were constructed and
the statistical data were calculated. For calibration
curves in the range of 0.5–50 μg/ml, 5 ml (instead of
2 ml) of rizatriptan solution were used.
Precision and accuracy
To find out the precision and accuracy, three sets of dif-
ferent solutions of rizatriptan at three different concen-
tration levels for each calibration range were prepared in
triplicate and measured for 3 days. The within-day and
between-day precision and accuracy were calculated.
Results and discussion
Absorption spectra
The absorption spectra of the yellow ion-pair complex
between rizatriptan and BCG extracted with chloroform
measured in the range of 200–800 nm against the blank
solution showed a maximum absorbance at 416 nm
(Figure 2). This wavelength was used for spectrophoto-
mertic measurements. No absorption was observed in
the visible region for rizatriptan or BCG solutions alone.
As the maximum absorbance of the formed ion-pair















Figure 5 Stoichiometry of the ion-pair complex of rizatriptan
(4 × 10-4 M) and BCG (4 × 10-4 M) by Job’s continuous
variation method.
Table 1 Statistical data of calibration curves of rizatriptan
in standard solutions (n = 6)
Parameters Low range High range
Linearity range 0.50–50 μg/ml 10–100 μg/ml
Regression equation y = 0.025x
+ 0.004
y = 0.0107x +
0.0036
Standard deviation of slope 0.00033 0.00016
Relative standard deviation of slope (%) 1.32 1.53
Standard deviation of intercept 0.0015 0.0097
Correlation coefficient (r2) 0.9997 0.9998
Limit of Quantification (LOQ) 0.50 10.00
Limit of Detection (LOD) 0.17 3.33
Extinction coefficient (ε) 2.1 × 104 2.1 × 104
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within the minimum range.
Selection of the suitable pH
The ion-pair complexation was performed according to
the general procedure using Britton-Robinson buffer in
the range of 2–7. The results are demonstrated in
Figure 3. The maximum absorbance value was obtained
at pH 3.0. Using different kinds of buffers (phthalate,
Britton-Robinson or phosphate) at the same pH value,
the best results were observed in the presence of 1 ml of
phosphate buffer. It was also observed that higher ab-
sorption intensity was achieved when the buffer solution
was added after rizatriptan and BCG solution.
Selection of the reagent amount
To achieve complete reaction and maximum absorbance,
solutions of fixed concentrations of rizatriptan and varied
volumes (0.5–7 ml) of the BCG reagent were tested. The
results showed that maximum response was achieved by
using 6 ml of BCG reagent (Figure 4). Higher amounts
had no effect on the complex formation.
Selection of the extracting solvent
Different extracting solvents (chloroform, dichloromethane,
















Figure 6 Structure of the formed ion-pair complex of rizatriptan andabsorbance and higher selective extraction of the ion-pair
complex were achieved using chloroform as the extracting
solvent. It was also found that three times extraction with
5, 3 and 2 ml of solvent produced better results in compari-
son to one time extraction with 10 ml of chloroform.The effect of reaction time
Performing the ion-pair complexation in different time
intervals (0, 5, 10, 20, 30 and 60 min), showed that the
maximum absorbance was achieved immediately after
mixing the rizatriptan solution and BCG reagent in the
presence of buffer solution.
Stability of the ion-pair complex
The stability of the rizatriptan-BCG ion-pair complex
was evaluated for 24 h at room temperature. The results
showed that the formed complex was relatively stable
for at least 8 h (recovery > 95%).
Composition of the ion-pair complex
The Job’s method of continuous variations by using varied
volumes of equimolar solutions of rizatriptan (4 × 10-4M)
and BCG (4 × 10-4M) was employed to find out the stoi-
















Table 2 Precision and accuracy of the method for determination of rizatriptan in standard solutions
(n=9; 3 sets for 3 days)
Concentration
added (μg/ml)
Within-day (n=3) Between-day (n=9)
Found (μg/ml) CV (%) Error (%) Found (μg/ml) CV (%) Error (%)
0.50 0.49 ± 0.11 2.24 −2.00 0.49 ± 0.01 2.85 −2.00
5.00 5.01 ± 0.08 1.59 0.20 5.08 ± 0.10 1.96 1.60
50.00 50.32 ± 0.65 1.30 0.64 50.37 ± 0.88 1.75 0.74
10.00 9.86 ± 0.09 0.91 −1.40 9.94 ± 0.18 1.81 −0.60
50.00 49.83 ± 0.89 1.79 −0.34 50.33 ± 0.78 1.55 0.66
100.00 99.13 ± 1.52 1.53 −0.87 99.54 ± 1.79 1.80 −0.46
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rizatriptan (Figure 5). The plot reached a maximum
value at a mole fraction of 0.5 which indicated an equi-
molar (1:1) basis of the ion-pair complexation. The pro-




The calibration curves in the range of 0.5–50 μg/ml and
10–100 μg/ml were linear according to the statistical para-
meters shown in Table 1. High values of correlation coeffi-
cient and small values of the intercept were achieved.
Precision and accuracy
The within-day and between-day precision and accuracy
were evaluated for selected concentrations of rizatriptan
in one day and three consecutive days. The results are
summarized in Table 2. Low values of CV and error indi-
cated the acceptable precision and accuracy of the pro-
posed method.
Relative recovery
The relative recovery of rizatriptan from tablet samples
was about 98 percent which showed no interferences
from the excipients.
Application of the method
The proposed method was used for determination of riza-
triptan in tablet dosage forms. The proposed spectro-
photometric procedure was compared with a previously
published HPLC method [20]. No significant differences
(p<0.05) were observed using both methods.
Conclusion
The proposed spectrophotomertic method is relatively
simple, rapid, and cost effective and it is also accurate
and sensitive for determination of rizatriptan in bulk
powder and tablet dosage forms. No special sample
preparation is needed and no interferences from tablet
excipients were observed. The limit of determination ofthis method is lower than other previously reported
spectrophotometric methods. Therefore, the validated
method could be useful for routine quality control
assay of rizatriptan in pharmaceutical raw material
and dosage forms.
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